WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 571472

CAS#: 384376-42-5

Description: D75-4590 is a β-1,6-Glucan inhibitor. These inhibitors work as antifungal drugs by targeting the fungal cell wall. As glucan is a major component of the cell wall, specifically β-1,6-Glucan, these drugs can help fight fungal infections by degrading glucan or stopping production by inhibiting its synthase. D75-4590 is a pyridobenzimidazole derivative that achieves this function, and is effective against Candida strains (even fluconazole-resistant strains). D11-2040 and D21-6076 are antifungal derivatives of D75-4590.

Chemical Structure

CAS# 384376-42-5

Theoretical Analysis

MedKoo Cat#: 571472
Name: D75-4590
CAS#: 384376-42-5
Chemical Formula: C21H27N5
Exact Mass: 349.2266
Molecular Weight: 349.48
Elemental Analysis: C, 72.17; H, 7.79; N, 20.04

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: D75-4590; D754590; D75 4590

IUPAC/Chemical Name: 1-{[2-(Diethylamino)ethyl]amino}-2-ethyl-3-methylpyrido[1,2-a]benzimidazole-4-carbonitrile


InChi Code: InChI=1S/C21H27N5/c1-5-16-15(4)17(14-22)21-24-18-10-8-9-11-19(18)26(21)20(16)23-12-13-25(6-2)7-3/h8-11,23H,5-7,12-13H2,1-4H3


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 349.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Kitamura A, Someya K, Hata M, Nakajima R, Takemura M. Discovery of a small-molecule inhibitor of {beta}-1,6-glucan synthesis. Antimicrob Agents Chemother. 2009 Feb;53(2):670-7. doi: 10.1128/AAC.00844-08. Epub 2008 Nov 17. PubMed PMID: 19015325; PubMed Central PMCID: PMC2630612.

2: Kitamura A, Someya K, Okumura R, Hata M, Takeshita H, Nakajima R. In vitro antifungal activities of D11-2040, a beta-1,6-glucan inhibitor, with or without currently available antifungal drugs. Biol Pharm Bull. 2010;33(2):192-7. PubMed PMID: 20118539.

3: Liu N, Tu J, Dong G, Wang Y, Sheng C. Emerging New Targets for the Treatment of Resistant Fungal Infections. J Med Chem. 2018 Jan 16. doi: 10.1021/acs.jmedchem.7b01413. [Epub ahead of print] PubMed PMID: 29294275.

Additional Information

There is increasing morbidity and mortality resulting from invasive fungal infections (IFIs) and antifungal drug resistance. As a result, several drug therapies are addressing the need by discovering and designing new antifungal drug targets and mechanisms, specifically against the most common fungi causing IFIs: Candida, Cryptococcus, and Aspergillus species. Existing drugs (polyenes, azoles, and echinocandins) have limited clinical efficacy, narrow antifungal spectrum, unfavorable pharmacokinetic profiles, significant side effects, drug−drug interactions, and resistance issues.